CME Group Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com──────────**BETA FINCH — CME GROUP Q2 2026 EARNINGS BREAKDOWN**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into CME Group's second quarter 2026 results — and trust me, there is a LOT to unpack here beyond just the numbers.JORDAN: Yeah, this one's spicy. We've got record revenue, but the real story is CME going toe-to-toe with the entire perpetual futures narrative that's been dominating headlines.ALEX: Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Solid. Okay, let's start with the numbers, because they're genuinely strong.ALEX: Right. Revenue came in at just over $1.7 billion, up 1% year-over-year — that's a record for a second quarter and the second-highest quarterly revenue in company history, only behind Q1 of this year. Average daily volume was 29.8 million contracts, the second-best Q2 ever, within 1% of last year's record.JORDAN: And the real headline for me is market data — $238 million in revenue, up 20% year-over-year. That's 33 consecutive quarters of year-over-year growth. Thirty-three! That's not a hot streak, that's a business model.ALEX: It's wild. And adjusted EPS came in at $2.99, up 1% from last year, with a 69.5% adjusted operating margin. For a company this size, that margin is just remarkable.JORDAN: They also returned $1.2 billion to shareholders in the quarter — $468 million in dividends, $695 million in buybacks. And CFO Lynne McGregor, who's stepping into a bigger strategic role, noted July is already tracking 18% ahead of last year. So momentum's not slowing down.ALEX: Okay, now let's get into the thing everyone on the call wanted to talk about — perpetual futures. Multiple analysts pressed CEO Terry Duffy on this, and he came out swinging.JORDAN: He really did. His argument, basically boiled down: perpetuals are functionally leveraged spot products dressed up as futures. No expiration date, funding rate resets, auto-liquidation mechanics — and he says none of that works for the institutional risk managers who make up 94% of CME's volume.ALEX: He had this great anecdote about calling the CEO of a major energy trading firm and asking — I think he said nineteen times — whether they wanted CME to list a perpetual oil contract. Answer: no, every time. They said they couldn't risk-manage their book with something that just tracks leveraged spot price.JORDAN: And on the crypto comparison — which is really the only apples-to-apples perpetuals data point that exists right now — CME's Tim McCourt laid out some pretty stark numbers. CME's doing $4.5 to $6.5 billion a day in crypto derivatives volume, versus about $270 million a day for a Bitcoin perpetual that a competitor, Kalshi, launched in July. Open interest gap was even bigger — $9-10 billion at CME versus $10 million for that perpetual product.ALEX: So the message is basically: "We could launch these tomorrow if there were real demand, but the demand just isn't showing up where it matters."JORDAN: Right, and Duffy was pretty direct that this isn't a defensive posture — CME says it has contract specs ready to go. It's a "we'll do it when it makes sense" stance, not a "we can't compete" stance.ALEX: Let's talk product pipeline, because there's a lot coming. Twenty-four-seven crypto futures trading launched this quarter. This weekend, round-the-clock gold trading goes live. Next week, Single Stock futures relaunch — this is CME's second attempt at that product after a failed joint venture back in 2000.JORDAN: Duffy's reasoning on timing there was interesting — he basically said the market has evolved, equity valuations are much higher now, and inThis episode includes AI-generated content.